Fapon Bio Develops Anti-CD3 Nanobody for Next-Gen TCE Therapies

Fapon Biopharma unveiled its novel anti-CD3/TCR nanobody platform at the 2025 Chinese Biopharmaceutical Association (CBA)-China Annual Meeting, featuring cross-species (human/monkey) binding and enhanced stability for T-cell engager (TCE) development.

The platform has generated multiple TCE candidates including: CD19/BCMA dual-targeting TCE for systemic lupus erythematosus (SLE); Tri-specific TCE with co-stimulatory signals for solid tumours; CD8⁺ T cell-biased TCE for solid tumours.

Vice-president Di Lu highlighted its advantages over conventional antibodies in safety and druggability. Fapon's integrated R&D capabilities span discovery, CMC and early clinical development across oncology and autoimmune diseases.

Daily News
AbbVie Reports 2025 Growth Post-Humira as Skyrizi Reaches USD 17.6b
2026-02-06
Henlius Licenses PD-1 mAb Serplulimab to Eisai for Japanese Market
2026-02-06
Lilly Posts Record 2025 Revenue of USD 65.2b, Led by Tirzepatide
2026-02-06
GSK Reports 7% Growth in 2025 Led by Specialty Medicines and Oncology
2026-02-05
Novo's 2025 Revenue Reaches USD 46.9b as Semaglutide Hits USD 34.6b
2026-02-05
Latest Report
Insights into China’s Innovative Drug R&D and Transaction Trends_PharmCube
Details